Valuation : MannKind Corporation

Market Cap 1.31B 1.12B 1.06B 965M 1.81B 123B 1.81B 12.49B 4.85B 63.24B 4.9B 4.8B 204B P/E 2026 *
-22.2x
P/E 2027 * -3,248x
Enterprise Value 1.31B 1.12B 1.06B 965M 1.81B 123B 1.81B 12.49B 4.85B 63.24B 4.9B 4.8B 204B EV / Sales 2026 *
2.94x
EV / Sales 2027 * 2.59x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day+2.53%
1 week+2.78%
Current month+1.25%
1 month+2.53%
3 months+15.34%
6 months+37.63%
Current year-28.40%
1 week 3.9
Extreme 3.9
4.1
1 month 3.63
Extreme 3.63
4.4
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
7/8/26 Sell

Director

-39,051 0.0122%
17/7/26 Sell

General Counsel

-24,109 0.0078%
17/7/26 Sell

Director

-52,485 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%+2.78%-23.97%-12.31% 1.31B
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -0.99%+0.51%+38.90%+165.92% 28.04B
Weighted average by Cap. -1.50%+0.19%+41.98%+144.35%

Financials

2026 *2027 *
Net sales 443M 382M 359M 328M 614M 41.87B 615M 4.24B 1.65B 21.48B 1.67B 1.63B 69.2B 504M 434M 408M 373M 697M 47.59B 699M 4.82B 1.87B 24.42B 1.89B 1.85B 78.66B
Net income -57.18M -49.2M -46.29M -42.29M -79.11M -5.4B -79.32M -547M -212M -2.77B -215M -210M -8.92B 27.12K 23.34K 21.96K 20.06K 37.52K 2.56M 37.62K 259K 101K 1.31M 102K 99.62K 4.23M
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
04/09/26 US$4.060 +2.53% 2,807,581
03/09/26 US$3.960 -1.98% 2,331,113
02/09/26 US$4.040 +1.51% 2,590,708
01/09/26 US$3.980 -0.75% 2,234,752
31/08/26 US$4.010 +1.52% 2,805,985
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.060USD
Average target price
7.969USD
Spread / Average Target
+96.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock